Skip to main content

Prostate Cancer Clinical Trials

Review the prostate cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 533

Evaluation of Zimberelimab, Etrumadenant, Quemliclustat and Stereotactic Body Radiation Therapy for the Treatment of Hormone Sensitive Oligometastatic Prostate Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Relugolix or Leuprolide for the Treatment of Cardiac Function in Patients with Prostate Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Relugolix in Combination with Radiation Therapy for Treating Patients with High Risk Prostate Cancer
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Bortezomib for the Treatment of Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion, BORXPTEN Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Prostatic Artery Embolization for the Treatment of Patients with Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Focal Cryotherapy for the Treatment of Intermediate Risk Prostate Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients with High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
High Dose Rate Brachytherapy Boost with Ultrahypofractionated Whole Pelvis Proton Radiation Therapy for the Treatment of High or Unfavorable Intermediate Risk Prostate Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Curcumin in Treating Patients with Prostate Cancer That Was Removed by Surgery
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Focal Therapy Combined with Androgen Deprivation Therapy for the Treatment of Localized Intermediate Risk Prostate Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Enzalutamide and Talazoparib with Androgen Deprivation Therapy for the Treatment of Patients with Prostate Cancer that is Metastatic to the Lymph Nodes at Diagnosis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
High Intensity Focused Ultrasound for the Treatment of Radiorecurrent Localized Prostate Cancer
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Status: Active
Location: NYP/Weill Cornell Medical Center, New York, New York
Risk Stratified De-escalated Hormone Therapy with Radiation Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Intraoperative Imaging with Indocyanine Green for the Improvement of Functional Outcomes in Patients with Prostate Cancer
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Nivolumab for the Treatment of DNA Repair-Mutated, Biochemically Recurrent Prostate Cancer, The NivoCure Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland